For the expanded composite outcome of EAC-confirmed MACE, revascularization, unstable angina pectoris requiring hospitalization or hospitalization for heart failure, treatment with SEM was associated with numerically lower events in the study population, compared with placebo (Table 29)
These include amylase, proteases, cellulase, xylose isomerase, sucrase, maltase, lactase, and glutenase, which may help support the digestion of various ingested compounds like complex carbohydrates, plant-based proteins, sugar, lactose, and gluten
Currently 18% of the U.S
[1] [2] Strategic timing of tirzepatide administration may help some patients manage common adverse effects, particularly gastrointestinal symptoms that occur during initial treatment and dose escalation
Results typically last three years or longer